Scholar Rock/$SRRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Scholar Rock
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Ticker
$SRRK
Sector
Primary listing
Employees
289
Headquarters
Website
Scholar Rock Metrics
BasicAdvanced
$6.2bn
-
-$3.43
0.71
-
Price and volume
Market cap
$6.2bn
Beta
0.71
52-week high
$58.49
52-week low
$27.07
Average daily volume
1.6m
Financial strength
Current ratio
8.639
Quick ratio
8.407
Long term debt to equity
72.315
Total debt to equity
74.516
Interest coverage (TTM)
-44.54%
Profitability
EBITDA (TTM)
-407.971
Management effectiveness
Return on assets (TTM)
-54.30%
Return on equity (TTM)
-138.94%
Valuation
Price to book
22.32
Price to tangible book (TTM)
22.32
Price to free cash flow (TTM)
-20.277
Free cash flow yield (TTM)
-4.93%
Free cash flow per share (TTM)
-2.551
Growth
Earnings per share change (TTM)
23.25%
3-year earnings per share growth (CAGR)
2.45%
What the Analysts think about Scholar Rock
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Scholar Rock Financial Performance
Revenues and expenses
Scholar Rock Earnings Performance
Company profitability
Scholar Rock News
AllArticlesVideos
Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026
Reuters·7 hours ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.